NASDAQ:DFTX
Definium Therapeutics, Inc.
Definium Therapeutics, Inc. reported net income of −$183.8M in fiscal 2025. The diluted share count rose 26.8%.Summary generated from Definium Therapeutics, Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROIC−251.1%
Return on equity−64.1%
Debt / equity0.12
Free cash flown/a
FCF marginn/a
Share count change+26.8%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −94 | −66 | −94 | −104 | −166 |
| Net income | −93 | −57 | −96 | −109 | −184 |
| Free cash flow | n/a | n/a | n/a | n/a | n/a |
Recent filings
- 4Insider transaction report
Sep 29, 2026 - 4Insider transaction report
Sep 29, 2026 - 8-KRegulation FD disclosure
Sep 14, 2026 - 8-KOther events
Sep 8, 2026 - 8-KRegulation FD disclosure
Aug 12, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 8-KEntry into a material agreement
Jun 24, 2026